It’s mission critical this time as biotech looks to bounce back

Fireside chat

An in-depth discussion featuring Sage CEO Barry Greene and Endpoints’ EIC John Carroll.

sponsored by

The biopharma industry in 2023

Endpoints EIC John Carroll joins Catalent’s Alessandro Maselli to chart the waters ahead for biopharma.

sponsored by

Dealmaking in 2023

Our panel of veteran industry dealmakers will take a look at the top trends as we enter a new year at the bargaining table.

sponsored by

What's really driving the cost of healthcare and drugs in 2023?

How do we break the deadlock on the debate over drug prices? Our panel brings together the drug industry, a PBM trying to create new dynamics in discussions on cost, and the head of ICER for a discussion on where the conversation over costs needs to go next.

sponsored by

Fireside chat

A one-on-one conversation with Metagenomi Chief Investment Officer Simon Harnest and Endpoints’ EIC John Carroll.

sponsored by

Coworking lounge

Coworking lounge at our event venue blocks away from Union Square — network with Endpoints readers, access WiFi, unlimited coffee, snacks, charging areas + more. First come first serve, includes lounge areas & cafe style seating.

Brought to you by

Fireside chat

An in-depth discussion featuring Endpoints EIC John Carroll and ARCH’s Robert Nelsen.

Exceptional biopharma comms in a post-social media age

Social media has matured and the number of platforms that your audiences are engaged with are as complex as ever. How are biopharma pros navigating this new era and delivering transparent, accurate, and timely information to stakeholders from patients to investors? Which platforms work best for the variety of campaigns PR teams are expected to deliver? Whether you are a seasoned communications pro or new to the field, this discussion is sure to provide valuable insights and best practices as we enter the post-social media age in 2023 and beyond.

sponsored By

AI in biopharma 2023 — there's no looking back

From discovery through trials, we're beyond the early stages of AI in biotech R&D. When the mission is to get to patients faster, drug developers are increasingly looking at technology for the answers. Beyond the initial hype, where is AI poised to make meaningful contributions to R&D? Endpoints publisher Arsalan Arif is convening a panel of leading experts to discuss the state of AI in biotech and the outlook for 2023. How are we getting higher quality targets into clinical trials? How is AI playing a role in clinical trial design? What's the impact of protein structure predicting in drug discovery? What's the outlook for AI in 2023?

sponsored by

This is how we cure cancer

One of the key trends in oncology R&D right now is moving new cancer therapies into the adjuvant arena, combining with better diagnostics and earlier diagnosis to hit cancer at a point it can still be forced into remission. In this roundtable discussion we’ll look at some of the latest advances in combinations and early detection that will give patients the best shot at a curative therapeutic program. Moderated by John Carroll.

sponsored By

Coworking lounge

Coworking lounge at our event venue blocks away from Union Square — network with Endpoints readers, access WiFi, unlimited coffee, snacks, charging areas + more. First come first serve, includes lounge areas & cafe style seating.

Brought to you by

Fireside chat

An in-depth discussion featuring Endpoints News Founder Arsalan Arif and and Novovax’s John J. Trizzino.

sponsored By

Did the IRA kill that drug?

Pharma companies were loud and clear ahead of the passage of Medicare price setting legislation in the IRA. Once passed, they threatened, they’d start to cull out drugs that no longer worked in the new math of the legislation. And within weeks we began to see that happen. How big will the impact really be? What else should be expected? And are developers simply finding a convenient villain to blame? Zachary Brennan, Endpoints regulatory expert, digs in.

Fireside with Ivan Cheung

An in-depth discussion featuring Endpoints News Executive Editor Drew Armstrong and Eisai US Chief Executive Officer Ivan Cheung.

Capital Markets

The IPO window is still closed, cash on hand is dwindling for some companies, interest rates remain high, and a hoped-for boom in M&A hasn't materialized. Our expert panel will look at the capital environment in biotech, looking ahead to when the current tightness might end and also at how companies are coping now, how they've being steered by venture investors and partners, and what the options are for those who need to raise fresh cash.

Fireside Chat

One-on-one chat featuring a member of the Endpoints editorial team and an industry leader.